TRIM21 and synovial sarcoma: To determine whether the significant differences in laboratory findings reported in Table 1 were skewed by reduced diagnoses of SS and SLE in the isolated anti-Ro52/TRIM21 group, we conducted further analyses excluding patients with SS or SLE.